← Leaderboards
Juan C. De La Torre
Scripps Research Institute
$34,810,527
Attributed
$40,524,450
Total exposure
34
Grants
24
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12.4M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,524,450 · 34
By mechanism
R01$18,367,571 · 10
U19$6,869,333 · 1
R21$5,051,117 · 10
G20$3,869,562 · 1
R56$2,551,817 · 5
P01$1,252,678 · 2
Top collaborators
- Luis Martinez-Sobrido9 shared
- Slobodan Paessler6 shared
- Dianne B Mckay2 shared
- Igor S. Lukashevich1 shared
Others in their field
Top investigators on “Lymphocytic Choriomeningitis Virus”
- Michael B Oldstone · Scripps Research Institute$24,028,702
- Arlene H Sharpe · Harvard Medical School$19,979,288
- Elina I Zuniga · University Of California, San Diego$18,963,351
- E. John Wherry · Emory University$18,691,932
- Rama Rao Amara · Emory University$15,655,138
- J. Lindsay Whitton · Scripps Research Institute$11,715,760
Research focus
Lymphocytic Choriomeningitis VirusCellsVirusViralInfectionAntiviral AgentsBaseArenavirusVirus DiseasesRibavirinCombatVaccinesProteinsVirus ReplicationMediatingProductionViral Hemorrhagic FeversCultured CellsPropertyPathogenMolecularResponseNeglectClinically Significant
Grant awards (84)
Novel Lassa fever live-attenuated vaccine platform with safety features ensuring unbreachable attenuation$469,396
U01 · FY2025 · AI · contact PI
Novel Lassa fever live-attenuated vaccine platform with safety features ensuring unbreachable attenuation$490,396
U01 · FY2024 · AI · contact PI
Role of NLRP3 signals in ischemia/reperfusion-induced organ injury$904,991
R01 · FY2023 · DK
Designing mammarenavirus live vaccines with unbreachable attenuation$221,875
R21 · FY2023 · AI · contact PI
Development and validation of antivirals against hemorrhagic fever viruses of pandemic concern$6,869,333
U19 · FY2022 · AI · contact PI
Improving The Scripps Research Institute BSL3 Capabilities to Combat Viruses of Pandemic Concern$3,869,562
G20 · FY2022 · AI · contact PI
Role of NLRP3 signals in ischemia/reperfusion-induced organ injury$924,366
R01 · FY2022 · DK
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus Biology$434,375
R01 · FY2022 · AI · contact PI
Designing mammarenavirus live vaccines with unbreachable attenuation$266,250
R21 · FY2022 · AI · contact PI
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus Biology$434,375
R01 · FY2021 · AI · contact PI
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus Biology$434,375
R01 · FY2020 · AI · contact PI
Molecular Basis of Viral Pathogenesis$363,730
T32 · FY2020 · AI · contact PI
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus Biology$457,750
R01 · FY2019 · AI · contact PI
A Virus-Free Cell Platform To Discover Inhibitors Of Lassa Fever Virus$433,125
R01 · FY2019 · AI · contact PI
Protecting Against Main Hemorrhagic Fever-Causing Arenaviruses With A Single Live-Attenuated Vaccine$290,250
R21 · FY2019 · AI · contact PI
Reverse Genetics To Forward The Pan-Lassa Fever Vaccine Lead Candidate ML29$851,962
R56 · FY2018 · AI
A Virus-Free Cell Platform To Discover Inhibitors Of Lassa Fever Virus$385,000
R01 · FY2018 · AI · contact PI
Protecting Against Main Hemorrhagic Fever-Causing Arenaviruses With A Single Live-Attenuated Vaccine$241,875
R21 · FY2018 · AI · contact PI
Modulation of Lassa Virus vRNP Activity By Host Cell Factors$241,266
R21 · FY2018 · AI · contact PI
A Virus-Free Cell Platform To Discover Inhibitors Of Lassa Fever Virus$433,125
R01 · FY2017 · AI · contact PI
Modulation of Lassa Virus vRNP Activity By Host Cell Factors$312,516
R21 · FY2017 · AI · contact PI
A General Molecular Strategy for Attenuation of Human Pathogenic Arenaviruses$240,625
R21 · FY2017 · AI · contact PI
A General Molecular Strategy for Attenuation of Human Pathogenic Arenaviruses$288,750
R21 · FY2016 · AI · contact PI
Activity-Based Protein Profiling of Arenavirus-Host Interactions$288,750
R21 · FY2016 · AI · contact PI
Profiling Serine Hydrolase Activity At The Virus-Host Interface$240,625
R21 · FY2016 · AI · contact PI
Recombinant life attenuated vaccine against Argentine hemorrhagic fever$957,982
R01 · FY2015 · AI
Profiling Serine Hydrolase Activity At The Virus-Host Interface$284,250
R21 · FY2015 · AI · contact PI
Activity-Based Protein Profiling of Arenavirus-Host Interactions$236,875
R21 · FY2015 · AI · contact PI
Recombinant life attenuated vaccine against Argentine hemorrhagic fever$964,053
R01 · FY2014 · AI
Recombinant life attenuated vaccine against Argentine hemorrhagic fever$904,246
R01 · FY2013 · AI
Recombinant life attenuated vaccine against Argentine hemorrhagic fever$865,253
R01 · FY2012 · AI
Targeting the processing of the arenavirus glycoprotein for anti-viral therapy.$465,302
R01 · FY2012 · AI · contact PI
Anti-interferon Activity of the Arenavirus Nucleoprotein$440,310
R01 · FY2012 · AI · contact PI
Recombinant life attenuated vaccine against Argentine hemorrhagic fever$901,836
R01 · FY2011 · AI
Targeting the processing of the arenavirus glycoprotein for anti-viral therapy.$465,302
R01 · FY2011 · AI · contact PI
Anti-interferon Activity of the Arenavirus Nucleoprotein$440,310
R01 · FY2011 · AI · contact PI
Reverse Genetics of Arenaviruses.$417,891
R01 · FY2011 · AI · contact PI
Targeting the processing of the arenavirus glycoprotein for anti-viral therapy.$470,003
R01 · FY2010 · AI · contact PI
Immune cell dynamics during central nervous system viral infection$459,450
R01 · FY2010 · AI · contact PI
Anti-interferon Activity of the Arenavirus Nucleoprotein$444,757
R01 · FY2010 · AI · contact PI
Reverse Genetics of Arenaviruses.$422,111
R01 · FY2010 · AI · contact PI
Immune cell dynamics during central nervous system viral infection$481,925
R01 · FY2009 · AI · contact PI
Targeting the processing of the arenavirus glycoprotein for anti-viral therapy.$474,750
R01 · FY2009 · AI · contact PI
Reverse Genetics of Arenaviruses.$426,375
R01 · FY2009 · AI · contact PI
Anti-interferon Activity of the Arenavirus Nucleoprotein$311,793
R01 · FY2009 · AI · contact PI
Anti-interferon Activity of the Arenavirus Nucleoprotein$471,125
R56 · FY2008 · AI · contact PI
Biology of Animal Nuclear Mononegaviruses$444,400
R56 · FY2008 · AI · contact PI
Immune cell dynamics during central nervous system viral infection$386,530
R56 · FY2008 · AI · contact PI
Novel Strategies to Target Arenaviruses$330,586
U54 · FY2008 · AI · contact PI
Reverse Genetics of Arenaviruses.$210,572
R01 · FY2008 · AI · contact PI
GLOBAL IDENTIFICATION OF CELLULAR INTERACTING PARTNERS FOR ARENAVIRUS Z PROTEIN$8,075
P41 · FY2008 · RR · contact PI
Reverse Genetics of Arenaviruses$397,800
R56 · FY2007 · AI · contact PI
Novel Strategies to Target Arenaviruses$320,230
U54 · FY2007 · AI · contact PI
Neuroimmunologic Disorders Induced by Chronic Viral Infection$203,073
R21 · FY2007 · NS · contact PI
Novel Strategies to Target Arenaviruses$301,039
U54 · FY2006 · AI · contact PI
Identification of Borna Disease Virus Receptor Proteins$272,297
R21 · FY2006 · AI · contact PI
Neuroimmunologic Disorders Induced by Chronic Viral Infection$250,965
R21 · FY2006 · NS · contact PI
REVERSE GENETICS OF ARENAVIRUSES$310,275
R01 · FY2005 · AI
Novel Strategies to Target Arenaviruses$275,305
U54 · FY2005 · AI
Identification of Borna Disease Virus Receptor Proteins$232,375
R21 · FY2005 · AI
Molecular Biology of Borna Disease Virus (BDV)$351,880
R01 · FY2004 · NS
REVERSE GENETICS OF ARENAVIRUSES$310,275
R01 · FY2004 · AI
Novel Antiviral Strategy to Combat Arenaviruses$234,625
R21 · FY2004 · AI
Aminoglycoside Antivirals to Combat Arenaviruses$234,625
R21 · FY2004 · AI
PROTEOME OF ARNAVIRUS RING FINGER Z PROTEIN$3,615
P41 · FY2004 · RR
Molecular Biology of Borna Disease Virus (BDV)$351,880
R01 · FY2003 · NS
REVERSE GENETICS OF ARENAVIRUSES$310,275
R01 · FY2003 · AI
Aminoglycoside Antivirals to Combat Arenaviruses$234,625
R21 · FY2003 · AI
Novel Antiviral Strategy to Combat Arenaviruses$234,625
R21 · FY2003 · AI
Molecular Biology of Borna Disease Virus (BDV)$351,880
R01 · FY2002 · NS
REVERSE GENETICS OF ARENAVIRUSES$310,275
R01 · FY2002 · AI
PERSISTANT VIRUS INFECTION LEADING TO DISORDERS IN ENDOCRINE AND CNS FUNCTION$178,517
P01 · FY2002 · AG
CORE-- MOLECULAR BIOLOGY$178,517
P01 · FY2002 · AG
REVERSE GENETICS OF ARENAVIRUSES$292,902
R01 · FY2001 · AI
PERSISTANT VIRUS INFECTION LEADING TO DISORDERS IN ENDOCRINE AND CNS FUNCTION$149,274
P01 · FY2001 · AG
CORE-- MOLECULAR BIOLOGY$149,274
P01 · FY2001 · AG
CORE-- MOLECULAR BIOLOGY$0
P01 · FY2001 · AG
PERSISTANT VIRUS INFECTION LEADING TO DISORDERS IN ENDOCRINE AND CNS FUNCTION$0
P01 · FY2001 · AG
BORNA VIRUS--AN EMERGING NEUROTROPIC PATHOGEN IN HUMANS$218,998
R01 · FY2000 · MH
MOLECULAR BIOLOGY OF BORNA DISEASE VIRUS (BDV)$193,228
R01 · FY2000 · NS
PERSISTANT VIRUS INFECTION LEADING TO DISORDERS IN ENDOCRINE AND CNS FUNCTION$149,274
P01 · FY2000 · AG
CORE-- MOLECULAR BIOLOGY$149,274
P01 · FY2000 · AG
CORE-- MOLECULAR BIOLOGY$149,274
P01 · FY2000 · AG
PERSISTANT VIRUS INFECTION LEADING TO DISORDERS IN ENDOCRINE AND CNS FUNCTION$149,274
P01 · FY2000 · AG